- Sharing the latest trends of new domestic anti-cancer drug pipelines on November 19 

Incurix CEO Kyung-Chae Jeong will attend the symposium hosted by the National OncoVenture (NOV) of the National Cancer Center, as a speaker representing innovative new drug development experts in Korea. On November 19, the National OncoVenture (NOV), supported by the Ministry of Health and Welfare, will co-host the ‘NOV-FEBPS Anti-cancer Symposium’ with the FEBPS (Foreign Experienced Korean Biotech/Pharmaceutical Societies), which is an expert group of new drug development.

The symposium, which will be held online under the theme of ‘Korea Oncology Drug Pipelines,’ was planned to share the results of a virtual new drug development model and exchange information. “We expect to share the R&D status of representative new drug programs, which are the main achievements of the NOV project, and share expertise in new drug development as well as know-how on use of network and infrastructure to strengthen capabilities in new drug development,” Park Young-hwan, Head of the NOV, said. The NOV is a government project that jointly develops and licenses candidate substances for new anti-cancer drugs with domestic industry and academia research institutes. Currently, 10 promising anti-cancer drugs are under development, among the 20 projects thathave been developed since June 2011. “Established in 2012, FEBPS is a group of new drug development experts who returned to Korea after researching at global pharmaceutical companies and biotechs. They are contributing to domestic new drug development and the growth of the bio industry based on their ample R&D and commercialization experiences overseas,” FEBPS chairperson Jung-sik Song (Professor at Yonsei University’s School of Medicine) said. He added, “We hope this symposium will contribute to new drug development.” 

http://medicalworldnews.co.kr/news/view.php?idx=1510938723